A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE)
Combined ipilimumab, nivolumab, influenza vaccine, and SBRT in patients with PC was feasible but did not lead to objective responses, and thus did not satisfy the predefined criteria for expanding to complete accrual.
Authors
- Kasper Madsen (ORCID: https://orcid.org/0009-0006-7612-3906)
- Estrid Høgdall (ORCID: https://orcid.org/0000-0003-4689-5658)
- I‐Ming Chen (ORCID: https://orcid.org/0000-0002-4831-3781)
- Inge Marie Svane (ORCID: https://orcid.org/0000-0002-9451-6037)
- Julia S. Johansen (ORCID: https://orcid.org/0000-0002-4217-6560)
- Susann Theile (ORCID: https://orcid.org/0000-0001-9804-7744)
- Anders Toxværd (ORCID: https://orcid.org/0000-0002-2246-8259)
- Dorte Nielsen (ORCID: https://orcid.org/0000-0002-8766-8729)
- Torben Lorentzen (ORCID: https://orcid.org/0000-0002-4454-4005)
Institutions
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Gentofte Hospital (DK)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2025-04-20
- DOI
- https://doi.org/10.1016/j.iotech.2025.101054
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09